Moffitt Cancer Center’s Genitourinary Oncology Program provides state-of-the-art care and develops newer, more effective therapies for patients with prostate cancer. We also treat other genitourinary cancers of the male and female urinary systems (the bladder, kidney and ureters), as well as men’s cancers of the penis and testicles.
Our team features multiple disciplines, including physicians, nurses, clinical trial coordinators and other health care professionals who support the patient-physician relationship and the care of patients and their loved ones. We hold weekly conferences to discuss cases, obtaining several different specialists' feedback and determining the next steps for patient care. This interdisciplinary approach results in highly coordinated, expert, quality patient care and greater patient satisfaction.
Prostate, kidney, bladder and penile cancers can occur at any age but are far more frequent in older patients. Because Florida has many senior citizens, the incidence of certain urologic cancers is higher here than in other areas of the United States. Just a few years ago, a cure for many urologic cancers was a rarity. The trend today toward early detection of cancer is expected to lead to improved survival rates. Advances in surgical techniques and radiation therapy have helped to improve the quality of life of many patients with urologic cancers by reducing the incidence of impotence in men and the side effects related to the bowel and bladder.
Rising Prostate-Specific Antigen (PSA) Clinic
Patients can take advantage of a clinic for men with prostate cancer. The goal of this clinic is to study and identify treatments that are beneficial for early or recurrent prostate cancer. A number of standard and new therapies are being studied for their ability to lower the prostate-specific antigen (PSA) and inhibit the spread of disease to the bone and other distant sites.
Men in whom the PSA is rising after prostatectomy, radioactive seed therapy, external radiation or testosterone deprivation with Lupron, Zoladex or orchiectomy, are candidates for this clinic. To determine the best course of therapy, patients see an interdisciplinary team that includes specialists in urologic oncology, radiation oncology and medical oncology. Local therapy may include salvage surgery, brachytherapy, external-beam irradiation or cryosurgery. In all cases, patients should be seen at the earliest date possible. This allows the physician to provide a wider variety of treatment options.
Clinical studies also are available for men who are attempting to block the development of bone lesions or the spread of tumors to other parts of the body. For example, two current studies focus on controlling prostate cancer after local therapy and androgen deprivation (Lupron, Zoladex or orchiectomy) has failed. One study evaluates the effectiveness of early adrenal androgen hormone reduction, and the second study evaluates the effectiveness of strengthening the bone to resist prostate metastasis.
Advanced Cancer of the Prostate
A focus of Moffitt’s Genitourinary Oncology Program is to provide lifelong cancer care to patients with advanced cancer of the prostate. This includes treatment of the tumor, pain, anemia, bone complications, infections, weight loss, blood clots, and family and emotional issues as well as prevention of paralysis and referral to other experts.
An additional focus of the program is to respond to the needs of patients of advanced age who have advanced prostate cancer. The needs and desires of older patients may differ from younger patients. For example, younger patients often choose the most effective available therapies, and they may place very little emphasis on potential side effects. Moffitt’s Genitourinary Oncology Program works closely with the Moffitt Senior Adult Oncology Program to provide care and develop treatments for older patients.